fda ban on compounded tirzepatide is stopping COMPOUNDED TIRZEPATIDE Eli Lilly's tirzepatide is off
Description
Gastroenterology [Internet]
Clinical trials demonstrate tirzepatide users report slightly lower gastrointestinal distress rates during dose escalation phases compared to semaglutide cohorts
If you're not seeing results by week 46, PlexusDx recommends discussing whether dose escalation, dietary adjustments, or switching to tirzepatide (a dual GIP/GLP-1 agonist) may be more effective for your body
These are avoidable risks with proper handling
